Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer. Narasimhulu DM, McGree ME, Weaver AL, Jatoi A, et al. Gynecol Oncol 2020 Jun 6. pii: S0090-8258(20)31131.

Read + Share

Amedeo Smart

Independent Medical Education

Narasimhulu DM, McGree ME, Weaver AL, Jatoi A, et al. Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer. Gynecol Oncol 2020 Jun 6. pii: S0090-8258(20)31131.
PMID: 32518016